Russia captures key lithium deposit in Ukraine in move that could impact US mineral deal
Russian troops have seized control of a key lithium field in eastern Ukraine despite fierce resistance from Ukrainian forces — in a move that some analysts speculate could potentially impact the United States' mineral deal.
President Vladimir Putin's forces captured the village of Shevchenko in the Donetsk region, which is close to the lithium deposit, within the last few days, Russian officials declared Thursday.
The deposit, which is located on Shevchenko's eastern outskirts and covers roughly 100 acres, is believed to be one of Ukraine's most valuable lithium deposits and sits at a depth that would allow commercial mining.
Ukrainian servicemen of the 101st Guard Brigade Of General Staff prepare to fire a 122-mm howitzer D-30 toward Russian positions on the frontline in the Donetsk area on Wednesday.
VITALII NOSACH/EPA/Shutterstock
Some industry analysts warned of possible impacts to the US-Ukraine mineral deal given that the seizure deprives Kyiv of a critical asset it could have offered up as part of the long-awaited partnership.
'If Russian troops go further, capture more and more territory, they will control more and more mineral deposits,' Mykhailo Zhernov, director of the US company Critical Metals Corp, which previously held a license at the Shevchenko deposit, told the New York Times.
'It's an issue for this deal.'
The deal, which was inked in April, created a joint fund to boost the reconstruction of the war-torn nation and gave the US preferential access to investment in Ukraine's oil, gas and rare mineral industries.
Analysts suggested the ongoing Russian advancement and subsequent occupation of Ukrainian territory — including the likes of the Shevchenko deposit — would prove to be a challenge for the deal.
Workers operate machinery at an open-pit titanium mine in the Zhytomyr region back in February.
AFP via Getty Images
Russian forces have been inching toward the Shevchenko field for months and, at one point, were advancing on it from three different routes, according to open-source mapping from Deep State, an authoritative Ukrainian military blogging resource.
'The village of Shevchenko, which is located on the border with the Dnipropetrovsk region, is another settlement that has a lithium deposit,' Igor Klimakovsky, a Russian-appointed official in Donetsk, was quoted by Russian state media as saying.
'This was one of the reasons why the Ukrainian armed forces sent a huge number of their soldiers to hold it.'
Russian-backed officials have previously suggested the Shevchenko field will be developed when the situation permits.
There was no immediate comment from Ukraine in the wake of the Shevchenko capture.
With Post wires
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
3 Quantum Computing Stocks on Verge of a Breakout: QBTS, IONQ, QUBT
The quantum computing industry has seen a surge of attention in 2025, driven by a wave of technical breakthroughs and a rapid expansion in real-world applications. Once viewed as a far-off moonshot, quantum technology is now making tangible strides, with implications for cybersecurity, drug discovery, AI, and more. As investor interest accelerates, several quantum stocks appear poised for major breakouts. Three quantum stocks in particular stand out right now: Quantum Computing Inc. (QUBT), D-WAVE QUANTUM (QBTS), and IonQ (IONQ). Each is benefiting from strong price momentum and rising earnings estimates, key ingredients for breakout potential. On top of that, all three are forming bullish technical patterns that suggest the possibility of another major run in the near term. Image Source: Zacks Investment Research D-WAVE QUANTUM has emerged as a clear leader in the quantum computing space, with its stock gaining more than 1,000% since last fall. The company specializes in quantum annealing, a unique approach to quantum computing that is already being applied to real-world optimization problems in logistics, manufacturing, and AI. Currently holding a Zacks Rank #2 (Buy), D-Wave is benefiting from a wave of bullish sentiment, as analysts have unanimously raised earnings estimates. While the company remains unprofitable, its top-line growth trajectory is impressive, as sales are expected to surge 183% this year, followed by another 62% increase in 2026. From a technical perspective, QBTS is forming a bullish descending wedge pattern—a setup often associated with strong breakout potential. If the stock can break through resistance at the $14.70 level, it could trigger another explosive move to the upside, reinforcing its position as the momentum leader in the quantum space. Image Source: TradingView Quantum Computing Inc. has emerged as one of the stronger performers in the quantum computing sector over the past three months, signaling growing investor interest and building momentum. The company focuses on delivering affordable and accessible quantum solutions via its full-stack quantum platform, aiming to bridge the gap between quantum and classical computing. While QUBT currently holds a Zacks Rank #3 (Hold) due to a lack of earnings estimate revisions in the past two months, the revenue outlook remains highly encouraging. Though still unprofitable, the company is expected to grow sales by 34% this year and an impressive 200% in 2026, suggesting a potential inflection point in its growth trajectory. On the technical front, the stock is forming a tightening bullish flag pattern. If QUBT can break above key resistance at the $18.15 level, it could spark another strong rally and continue its recent streak of relative outperformance in the sector. Image Source: TradingView IonQ is one of the most well-known names in quantum computing, distinguished by its trapped-ion quantum technology and growing commercial traction. The company has secured strategic partnerships with tech giants like Microsoft Azure and Amazon Web Services, which are integrating IonQ's quantum capabilities into their cloud platforms. These collaborations not only validate IonQ's technology but also provide scalable pathways for adoption. The stock currently holds a Zacks Rank #2 (Buy), supported by substantial upward revisions to its earnings outlook. Analysts have raised earnings estimates by 43% for the current year and 28% for 2026, clear signs of improving sentiment. Though IonQ remains unprofitable, its top-line growth is robust, with revenue expected to climb 97% this year and 57% next year. From a technical standpoint, IONQ is forming a compressing bull flag pattern, a standard bullish continuation setup. If the stock can break above key resistance at $41.60, it should trigger a move toward new all-time highs, fueled by both momentum and the strength of its big-tech partnerships. Image Source: TradingView Quantum computing may still be in the early stages of commercialization, but investor enthusiasm is building fast, and with good reason. Technical progress is accelerating, enterprise adoption is growing, and Wall Street is beginning to recognize the long-term potential of the companies leading the charge. Among the emerging players, D-WAVE QUNATUM, IonQ, and Quantum Computing Inc. each offer a unique angle on the quantum revolution, backed by impressive revenue growth forecasts, rising analyst sentiment, and powerful chart setups. While these stocks remain volatile and speculative, they are showing all the technical and fundamental traits of breakout candidates. For investors willing to take on higher risk in pursuit of disruptive upside, these three quantum stocks are worth a close look as momentum continues to build in 2025. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IonQ, Inc. (IONQ) : Free Stock Analysis Report D-Wave Quantum Inc. (QBTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
41 minutes ago
- Yahoo
Congo and Rwanda Sign U.S.-Brokered Peace Deal With Trump in DC
The Democratic Republic of Congo and Rwanda signed a peace agreement aiming to end the conflict and open a shared stretch of East African mineral wealth to U.S. investment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced it has prevailed against the latest lawsuit filed by Advantech/Prime Success ('Advantech/Prime') in Hong Kong. This result follows Advantech/Prime's recently failed petition in New York last week, which was a repeated attempt by the purported PIPE Investors to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the payment of the US$55.00 per common share special cash dividend to valid shareholders of the Company as declared by the current SINOVAC Board. On June 24, Advantech/Prime delivered via email an ex parte Summons to SINOVAC, 1Globe Capital LLC ('1Globe') and OrbiMed Partners Master Fund Limited ('OrbiMed') for an 'interim-interim' injunction application (the 'Application'). Vivo Capital also sought to join the Application on June 26. After the emergent hearing at the High Court of Hong Kong on June 27, the court refused to grant any of the relief sought in the Summons. Among other things, the judge also criticized Advantech/Prime for: Failing to comply with the duty of full and frank disclosure in the Application; and The alleged urgency of the Application being self-induced by Advantech/Prime. The court also ordered that legal costs incurred in the Application by SINOVAC, 1Globe and OrbiMed be compensated by Advantech/Prime, with quantum to be assessed. Advantech/Prime's continued multi-jurisdictional lawfare is intended to interfere with rightful dividend payments to SINOVAC's valid shareholders and distract from its long history of self-serving schemes. These schemes include: Privatization attempt at a below-market price in 2016; Invalid PIPE transaction at a below-market price in 2018, which materially diluted SINOVAC shareholders and was made at a time when the Company did not need the capital; US$7.5 million debt investment into Sinovac Life Sciences Co., Ltd. ('SLS'), a wholly owned subsidiary of SINOVAC, in exchange for a 7.5% equity interest in SLS in 2020, at a time when the Company did not need the capital and which has resulted in over US$500 million of distributions made to Advantech/Prime to date while common shareholders have received nothing; and Baseless and wasteful legal action in 2025 to interfere with the dividend payment unless Advantech/Prime is able to double dip on dividends already received from SLS. The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
